

1 **The 10-year health impact, economic impact, and return on investment of the**
2 **South African molecular diagnostics programme for HIV, Tuberculosis and**
3 **SARS-CoV-2**

4
5 Brooke E. Nichols^{1,2*}, Alexandra de Nooy², Naseem Cassim^{3,4}, Lucia Hans^{3,4,5}, Manuel Pedro da Sil-
6 va^{3,4}, Kamy Chetty⁴, Kyra H. Grantz^{2,3}, Alvin X. Han⁶, Andrew N. Phillips⁷, Lise Jamieson^{8,9}, Lesley
7 E. Scott³, Wendy S. Stevens^{3,4*}

8
9 ¹ Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam UMC,
10 University of Amsterdam, Amsterdam, Netherlands

11 ² FIND, Geneva, Switzerland

12 ³ Wits Diagnostic Innovation Hub, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg,
13 South Africa

14 ⁴ National Health Laboratory Service (NHLS), Johannesburg, South Africa

15 ⁵ Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of Witwaters-
16 rand, Johannesburg, South Africa

17 ⁶ Department of Medical Microbiology, Amsterdam University Medical Center, Amsterdam, Netherlands

18 ⁷ Institute for Global Health, University College London, London, UK

19 ⁸ Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University of the Witwatersrand, Johan-
20 nesburg, South Africa

21 ⁹ The South African Department of Science and Innovation/National Research Foundation Centre of Excellence in Epidemi-
22 logical Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa

23
24
25 *Correspondence: brooke.nichols@finddx.org, wendy.stevens@wits.ac.za

26
27 **Keywords:** molecular diagnostics, tuberculosis, HIV, SARS-COV-2, return on investment, impact

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44 **ABSTRACT**

45

46 To ensure there is adequate investment into diagnostics, an understanding of the magnitude of
47 impact and return on investment is necessary. We therefore sought to understand the health
48 and economic impacts of the molecular diagnostic programme in South Africa, to deepen the
49 understanding on the broad value of diagnostics and guide future healthcare investments. We
50 calculated the 10-year (where data were available) total cost and DALYs averted associated
51 with molecular diagnosis of molecular TB testing (2013-2022), HIV viral load monitoring
52 (2013-2022), early infant diagnosis of HIV infection (2013-2022), and SARS-CoV-2 testing
53 (2020-2022). We then calculated the economic value associated with those health gains and
54 subsequent return on investment. Since the inception of the molecular diagnostics programme
55 in South Africa, 3,035,782 DALYs have been averted as a direct consequence of this pro-
56 gramme. This has generated an estimated \$20.5 billion in economic value due to these health
57 gains. The return on investment varied by specific diagnostic test (19.0 for tuberculosis, 1.4
58 for HIV viral load testing, 64.8 for early infant diagnosis of HIV, and 2.5 for SARS-CoV-2),
59 for an average of 9.9 for the entire molecular diagnostics programme between 2013 and
60 2022- or \$9.9 of value for each \$1 invested. The molecular diagnostics programme in South
61 Africa generated a significant amount of health gains and economic value associated with
62 these health gains, and the return-on-investment rivals other high-impact public health inter-
63 ventions such as childhood vaccination. Consequently, the molecular diagnostics programme
64 in South Africa is highly impactful, and will continue to be an excellent investment of South
65 African public health expenditure.

66

67

68

69

70

71

72

73

74

75

76

77

78 INTRODUCTION

79

80 Diagnostics play a vital role in ensuring quality health care at an individual level - through
81 disease diagnosis and screening as well as condition and treatment monitoring- and at the
82 global, national, or regional level through population disease surveillance (1). However, the
83 importance of diagnostics is frequently overlooked, resulting in underfunded or un-
84 der-resourced programmes (2). It is estimated that approximately 47% of the global popula-
85 tion have limited (if any) access to diagnostics, with alarming disparity between the Global
86 North and the Global South (2). Further, in comparison with other key healthcare elements,
87 like medicine, investment in diagnostics has historically been limited (3). This is concerning
88 given the direct connection between diagnosis and treatment- and has resulted in significant
89 empiric treatment across the disease spectrum, resulting in over-, under-, or incorrect treat-
90 ment (3). Additionally, although there is notable evidence of the substantial diagnostic gap in
91 many low- and middle-income countries (LMICs) - particularly for key disease areas like
92 HIV, tuberculosis (TB) and diabetes - there is little high-level literature which demonstrates
93 the direct and long-term health and economic impacts of strong and well-distributed public
94 health diagnostic programmes (4). This lack of evidence has limited the broad country-level
95 investments in diagnostics needed to ensure quality health care for all.

96

97 In terms of diagnostic access, South Africa is a leader within the South African Development
98 Community (SADC) region of sub-Saharan Africa. The country's National Health Laborato-
99 ry Service (NHLS) has a network of centralised molecular laboratory facilities and a daily
100 specimen transportation and results delivery system. There is cover at all public healthcare
101 facilities (PHCs) across the country, to provide diagnostic service support to ~85% of the to-
102 tal population and 100% of the public sector (5–7). Further, the NHLS conducts millions of
103 tests (both molecular and other) each year across a range of diseases, with nearly 107 million
104 tests being performed in 2021-2022 (8). Of these, approximately 10 million (9.4%) were mo-
105 lecular tests performed by the NHLS that support the long-standing HIV and TB treatment
106 programmes and more recently the severe acute respiratory syndrome coronavirus 2
107 (SARS-CoV-2) programme (8,9). These include HIV viral load testing, early infant diagnosis
108 (EID) for HIV infection, tuberculosis diagnosis, as well as SARS-CoV-2 diagnosis. Over the
109 last decade, molecular diagnostics have been introduced to each programme at different time
110 points. In 2004, molecular diagnostics were introduced for viral load monitoring of people
111 living with HIV on antiretroviral treatment. In 2011, the molecular diagnostics programme
112 for TB was introduced, replacing the standard of care for TB diagnosis at the time- the less
113 accurate smear microscopy. The molecular diagnosis programme expanded to include early
114 infant diagnosis of HIV in 2013. All these molecular platforms were leveraged for the diag-
115 nosis of SARS-CoV-2 infection in 2020.

116

117 To ensure there is ongoing adequate and sustainable investment in diagnostics, an under-
118 standing of the magnitude of impact and return on investment is necessary. We, therefore,
119 investigated the ten-year health and economic impacts of the public health molecular diag-

120 nostic programme in South Africa to deepen the understanding on the broad value of diag-
121 nostics to guide future healthcare investments.

122 **METHODS**

123 **Health impact**

124 The health impact, in terms of disability adjusted life years (DALYs), of each of the molecu-
125 lar diagnostic tools was calculated separately (Table 1). The health impact for TB, HIV viral
126 load, early infant diagnosis of HIV, and SARS-CoV-2 molecular testing were all sourced
127 from the literature or updated from existing models in the literature to understand both direct
128 clinical benefit of diagnosis and the extended benefits that diagnostic testing or monitoring
129 associated with a potential reduction in disease transmission can have. Impact can result from
130 multiple tests of a single individual (e.g. a TB diagnosis and a viral load monitoring test), and
131 these benefits are assumed to be additive.

132

133 *Diagnosis of tuberculosis*

134 The total number of TB tests conducted and number of positive diagnoses through the mo-
135 lecular diagnostics programme in South Africa was sourced from the literature(10). We
136 compared the total net impact of the molecular TB programme as well as the incremental
137 impact compared to if the sputum smear microscopy (SSM) programme had continued as it
138 was in 2010. For the counterfactual SSM programme, we assumed that 1.329 million tests per
139 year would be conducted from 2013-2022 (the same number of tests conducted in 2010 when
140 the SSM diagnostic programme was at capacity)(11). We then assumed a constant 10% prev-
141 alence of TB among those tested, and a 68% test sensitivity, and a 98% test specificity of
142 sputum smear microscopy (11). The sensitivity and specificity of Xpert MTB/Rif (12) was
143 assumed to be 85% and 98% respectively, and the sensitivity and specificity of Xpert
144 MTB/Rif Ultra (13), was assumed to be 91% and 99% respectively(14). For the total impact
145 of the programme, we multiplied the number of DALYs averted per correct positive TB di-
146 agnosis (assumed to be 1 DALY per diagnosis (15)) by the number of correct TB diagnoses
147 reported over time(10) (adjusting for test specificity). The benefits of the molecular pro-
148 gramme are results of the improved accuracy of molecular diagnostics compared to smear
149 microscopy for TB diagnosis.

150

151 *HIV viral load monitoring*

152 The HIV Synthesis model, an individual-based stochastic simulation model that includes HIV
153 transmission, progression, HIV-related treatment, and prevention interventions, was used to
154 estimate the DALYs associated with a viral load test (16,17). Two scenarios were run to tease
155 out the incremental benefit of viral load testing: 1) no viral load testing for three years, fol-
156 lowed by fully implemented viral load testing, and 2) fully implemented viral load testing
157 over 10 years. The difference in DALYs between the two scenarios provides an indication of
158 the DALYs averted because of viral load testing alone. To account for stochasticity, the mod-
159 el was run 300 times to produce an estimated average of 1250 DALYs averted per 3 months,
160 in the context of an adult population of 10 million with 207,000 viral load tests done per 3

161 months compared to when no viral load tests were done. This resulted in 0.006 DALYs
162 averted for each viral load conducted.

163

164 We then multiplied the number of viral load tests by the number of DALYs averted per viral
165 load conducted across the lifespan of the NHLS molecular diagnostics programme. Given
166 that we calculated the impact per viral load test conducted (rather than per elevated viral load
167 result), specific test accuracy parameters were not taken into account.

168

169 *HIV early infant diagnosis (EID)*

170 A model of quality assurance systems for HIV EID estimated the DALYs associated with
171 false negative test results with and without these systems for five countries(18). This study
172 indicated that the DALYs associated with an undiagnosed case of HIV among infants was
173 24.6 in South Africa. We then multiplied the number of DALYs averted by the number of
174 infants correctly diagnosed with HIV by year as reported in the literature(19) (adjusting for
175 test specificity). The sensitivity of HIV EID is assumed to be 99.3% and specificity 99.5%
176 (20), and a second test is required for confirmation.

177

178 *Diagnosis of SARS-CoV-2*

179 We used results from the Propelling Action for Testing and Treating (PATAT) simulation
180 model of SARS-CoV-2 transmission to estimate the DALYs averted per SARS-CoV-2 diag-
181 nostic test used in countries most similar to South Africa in terms of population demography
182 and household size (21,22).The impact of testing was primarily due to the reduction in the
183 number of onward infections following isolation of positive cases, rather than any specific
184 clinical impact. Individuals were assumed to reduce their number of community contacts by
185 50% on average after receiving a positive diagnosis but were not assumed to be able to effec-
186 tively isolate from household members. Given that the relative impact of testing for
187 SARS-CoV-2 is dependent on several parameters, we averaged the impact across effective
188 reproductive numbers of SARS-CoV-2 from 1.2-2.0, a testing rate of 100 tests per 100,000
189 per year, and minimal vaccine coverage. This resulted in 0.0651 DALYs averted per correct
190 positive test result (adjusted for test specificity). The sensitivity of molecular SARS-CoV-2
191 testing was assumed to be 99% and specificity 97% (23).

192

193 **Economic impact of health gains and return on investment (ROI)**

194 The total number of DALYs per health area were calculated per year and multiplied by the
195 GDP per capita per respective year to calculate the economic impact of the molecular diag-
196 nostics programme. Results are reported for each diagnostic test, and for the entire pro-
197 gramme (Table 1). No DALYs are averted for false positive results at the end of a diagnostic
198 algorithm, calculated using the average expected incidence of infection for each health area
199 and the specificity of the test or test algorithm. All health benefits and related economic gains
200 are expressed in terms of net present value of these gains. The health benefits (DALYs
201 averted) of a TB molecular diagnostic are expected to occur over a lifetime after the average
202 age of active TB disease, the benefits of HIV viral load testing were calculated over a

203 ten-year period (discounted at 3% annually), early infant diagnosis over a lifetime (discount-
 204 ed at 3% annually), and SARS-CoV-2 testing over 1 year (as such, not discounted).

205

206 Return on investment was calculated as the total economic impact per diagnostic tool divided
 207 by the total cost of all diagnostic tests required to generate that impact (including both “posi-
 208 tive” and “negative” tests). The total number of tests per programme, across the respective
 209 time periods considered, were taken from the literature for TB, HIV viral load, SARS-CoV-2,
 210 and EID (10,19,24–26). To calculate the number of HIV EID tests conducted on average for
 211 2020-2022, we used the number of live births to women living with HIV in 2021 (~275 527),
 212 the EID testing algorithm in South Africa and the coverage of testing at each part of the algo-
 213 rithm (averaged between NICD and DHIS sources). Given the relative overcounting of in-
 214 fants diagnosed with HIV reported in the literature(19), we also adjusted the numbers of posi-
 215 tive infants reported in 2013-2019 down to reflect this overcounting. We also adjusted for the
 216 neonatal mortality rate in South Africa for number of infants expected to be tested at 10
 217 weeks, and the number of infants testing positive who would not need to be retested (27).

218

219 The total costs were calculated as the 2022 test price per test in South African Rands (ZAR),
 220 converted to United States Dollar (USD) using average 2022 conversion rate (16.37 ZAR to
 221 1USD (28)), and multiplying each respective test cost by the total number of tests of that type
 222 conducted per year since the inception of the molecular diagnostic programme. “Deadweight”
 223 costs have been removed from the ROI analysis for TB diagnosis by using the appropriate
 224 incremental gains of the molecular programme (e.g. removing the costs associated with the
 225 counterfactual of keeping the sputum smear microscopy programme running at the same
 226 scale as when the molecular programme had been introduced). The additional costs incurred
 227 associated with false positive test results for TB and EID were calculated using prevalence of
 228 infection and test specificity of the testing algorithm. These additional costs included those
 229 for unnecessary treatment of drug sensitive TB disease, US\$ 112.70 (29), and unnecessary
 230 lifetime ART treatment cost for an misdiagnosed with HIV, US\$ 6,115 (discounted at 3% per
 231 year, assuming a life expectancy of 63.8 years) (18).

232

233 **Table 1. The cost per test and DALYs assumed per test or diagnosis as noted per disease area supported**
 234 **by the molecular diagnostics programme in South Africa**

Test con- ducted	Lab price per test (2022 USD)	Total cost per test (including staff and con- sumables for specimen col- lection) (2022 USD)	Source	DALYs avert- ed per diagno- sis or per test conducted	Source
TB molecular diagnosis	US\$ 14.01	US\$ 17.41	NHLS, (29)	1 per diagnosis	(15,29,30)
HIV viral load	US\$ 24.00	US\$ 28.10	NHLS, (29,30)	0.006 per test	(16,17,29–31)

				conducted	
Early infant diagnosis of HIV	US\$ 27.73	US\$ 28.9	NHLS, (29,30)	24.6 per diagnosis	(18,29,30)
SARS-CoV-2 molecular diagnosis	US\$ 24.56	US\$ 32.84	NHLS, (29)	0.0651 per positive diagnosis	(21,22,29)
Sputum smear microscopy*	US\$ 1.88	US\$ 4.06	(29)	1 per diagnosis	(15,29)

235 *Only used to calculate the counterfactual of the TB molecular diagnosis programme

236


237 Ethics

238 Solely aggregate data from previously published manuscripts was used for this analysis.
 239 (10,19,24,25). The data are available *open access* in each publication. Any missing data
 240 points were imputed rather than extracted from raw data.

241 RESULTS

242 Health Impact

243 Since the inception of the molecular diagnostics programme in South Africa, 3,035,782
 244 DALYs have been averted as a direct consequence of this programme. This includes 961,499
 245 incremental DALYs averted due to the diagnosis of TB (2013-2022) (incremental to a con-
 246 tinued smear microscopy programme, adjusting for false positive test results), 272,009 avert-
 247 ed due to HIV viral load tests (2013-2022), 1,700,208 due to early infant diagnosis
 248 (2013-2022), and 102,066 DALYs averted due to molecular SARS-CoV-2 testing
 249 (2020-2022). Figure one highlights the relative impact per year that each of the diagnostics
 250 has demonstrated.



251

252

253

254


255 **Figure 1.** The annual DALYs averted of South Africa's public sector molecular diagnostics programme for HIV,
256 TB and SARS-CoV-2 from 2013-2022

257

258 **Economic impact of health gains**

259 The total economic value of the molecular diagnostics programme due to health gains over
260 the ten-year period was US\$ 20.5 billion. This includes US\$ 6.4 billion in economic value
261 associated with improved health related to TB diagnosis (2013-2022), US\$ 1.8 billion for
262 HIV viral load testing (2013-2022), US\$ 11.6 billion for HIV early infant diagnosis
263 (2013-2022), and \$0.7 billion for SARS-CoV-2 testing (2020-2022) (Figure 2).

264



265

266 **Figure 2.** Annual economic value (in 2022 USD) associated with the health gains of the molecular diagnostics
267 programme for HIV, TB and SARS-CoV-2 from 2013-2022

268

269 **Return on investment**

270 The molecular TB diagnostics programme has cost an estimated US\$ 418 million over 10
271 years (for all TB diagnostics conducted plus costs associated with false positive test results),
272 while our counterfactual was assumed to cost \$81 million over the same period (for diagnos-
273 tics plus costs associated with false positive results), for an incremental cost of USD\$337
274 million of the molecular TB diagnostics programme. The total incremental economic value of
275 health gains associated with TB molecular diagnosis divided by the total incremental cost of
276 the molecular TB diagnostics programme resulted in a return on investment of 19.0- or
277 US\$ 19.0 of economic value for each US\$ 1 invested in diagnosis. The return on investment
278 for HIV viral load was 1.4, for HIV early infant diagnosis was 64.8, and for SARS-CoV-2

279 diagnosis was 2.5. Averaged across the whole molecular diagnostics programme, the average
280 return on investment was 9.9 - or US\$ 9.9 of economic gain related to improved health for
281 each US\$ 1 invested in diagnostics.

282

283 **Table 2.** The return on investment of the molecular diagnostics programme in South Africa, as expressed by the
284 total economic value of the health returns divided by the costs of conducting those tests across all years consid-
285 ered in this analysis

Test conducted	Economic value of health gains (2022 USD)	Total cost of implementation (2022 USD)	Return on investment
TB molecular diagnosis*	US\$ 6.4 billion	US\$ 337 million**	19.0
HIV viral load	US\$ 1.7 billion	US\$ 1.27 billion	1.4
Early infant diagnosis of HIV	US\$ 6.1 billion	US\$ 179 million**	64.8
SARS-CoV-2 molecular diagnosis	US\$ 0.6 billion	US\$ 273 million	2.5
Total	US\$ 20.5 billion	US\$ 2.1 billion	9.9

286 *Incremental benefit compared to a counterfactual of a smear microscopy programme

287 **Including healthcare costs associated with false positive test results

288 DISCUSSION

289

290 Generally, molecular testing has multiple roles in disease management, including diagnosis,
291 monitoring response to treatment and guiding decisions on appropriate management (e.g. in-
292 dications for HIV drug resistance tests) (9). Further, as compared to other diagnostic counter-
293 parts (like TB culture), molecular tests are frequently able to return accurate results more rap-
294 idly, and hence allow for action to be taken at an earlier stage (9). Thus, molecular testing, if
295 well-implemented, has the potential to greatly improve patient outcomes. This has been
296 shown by the public sector molecular diagnostics programme in South Africa that generated a
297 significant amount of health gains and economic value associated with these health gains. The
298 return on investment was ≥ 1.4 for all individual tests, as high as 64.8 and 9.9 on average-
299 suggesting excellent value for money across all molecular tests. These levels of return on in-
300 vestments for some tests rival childhood vaccination programmes (ROI 16)- often considered
301 one of the most valuable public health interventions (32,33). While the ROI value for each of
302 the individual types of molecular tests varied greatly, each still resulted in a positive impact
303 on the South African healthcare system given that all tests had at least a full ROI.

304

305 Comparing to other public health tools such as vaccines and therapeutics, for each specific
306 disease area is useful to understand the relative role of diagnostics as part of a public health
307 programme. For SARS-CoV-2, the ROI of vaccination has not been estimated for South Af-
308 rica, but in New York City was estimated to be 10 to 1(34). If adjusting this estimate for the
309 GDP per capita in South Africa, and the smaller proportion of people at risk for severe disease

310 and death in South Africa (due to demographic differences), the ROI for SARS-CoV-2 vac-
311 cines in South Africa might approach the value of diagnostics in South Africa. ROIs for spe-
312 cific therapeutics for SARS-CoV-2 in South Africa have not been calculated. Therapeutics
313 such as paxlovid, however, have not been available in South Africa. For both TB and HIV,
314 the return on investment for investments into vaccines has been effectively 0 (or negative)
315 given that there are no vaccines available for HIV, and no effective vaccines for adults for TB
316 (with the BCG vaccine for TB protective for <5-year-olds only). For HIV, the UNAIDS
317 “Fast-Track” strategy which focuses on investments in expanding HIV service coverage (as
318 opposed to maintaining constant coverage) estimates an approximate return on investment of
319 6.46 to 1 for Southern Africa (35,36). This contextualizes that viral load testing is comple-
320 mentary to a broader package of HIV-related services, with an ROI of 2, and that early infant
321 diagnosis remains to have an extraordinarily high ROI. With respect to TB, there also exists a
322 set of services which together have resulted in an estimated drop of more than 50% in the in-
323 cidence rate between 2011 and 2022 (37). While it is difficult to quantify exactly how much
324 each particular service (e.g. the increase in TB diagnostic capacity and accessibility, increased
325 TB treatment options and the impact of improved HIV services) has contributed towards re-
326 duced incidence, the introduction of Xpert MTB/Rif and Ultra and the scale-up of the molec-
327 ular testing programme has clearly contributed. Similarly in terms of investment, while there
328 is no specific literature available on the return-on-investment of TB diagnostics, studies have
329 shown that TB prevention and care yields a ROI of 43- implicitly including diagnosis-
330 whereas we have estimated the ROI of diagnosis aspect to prevention and care to be 19.0 (38).

331
332 These values represent one consistent methodological way to calculate impact, economic val-
333 ue, and ROI. There are several changes in the underlying assumptions that might influence the
334 direction of these values in both directions. Firstly, the average GDP per capita in South Afri-
335 ca may not reflect the burden of disease where the health gains occurred for each respective
336 disease (e.g. slightly lower burden of disease among higher household social economic index
337 score for tuberculosis infection) (39). If including these differences, the economic gains might
338 be slightly overstated where the benefits occurred amongst individuals with lower annual
339 GDP. We did not, however, want to weight the economic value of health differently among
340 the South African population. In the other direction, within the scope of this analysis, we have
341 only calculated the economic value of the health gains associated with molecular diagnostics
342 rather than the *total* economic benefit. The total economic benefit likely far exceeds what we
343 have estimated here- for example, the benefits associated with being able to return to work
344 after a negative SARS-CoV-2 test during the pandemic or benefits associated with the re-
345 duced frequency of healthcare clinic visits required after a suppressed viral load test- reducing
346 costs to individuals on antiretroviral treatment and possibly increasing economic activity due
347 to fewer days spent seeking care. Estimating the total value was outside the scope of this
348 analysis.

349
350 There were several limitations to our analysis. First, we did not include the value related to
351 drug susceptibility testing (DST) for tuberculosis given the paucity of literature on the

352 DALYs associated with TB resistance testing. If we had included that, the likely value and
353 impact of the molecular diagnostic programme would have only increased, especially since
354 the diagnosis of rifampicin resistant TB is provided simultaneously with the molecular diag-
355 nosis of TB. Second, for the incremental impact of the TB molecular diagnostics programme,
356 we assumed that the size of the smear microscopy programme would have held constant in
357 size from 2010 onwards. An expansion of this programme would have generated more health
358 effects and related economic value of health gains, resulting in a diminished incremental ben-
359 efit of the molecular programme. We made this assumption, however, given that the micros-
360 copy programme was already at capacity in 2010. Third, for the HIV viral load DALY calcu-
361 lations, it was assumed that individuals would be on a dolutegravir-based first line antiretro-
362 viral treatment regimen. The DALYs per viral load would have likely been greater in
363 pre-dolutegravir era, given that previous regimens were slightly less effective. This would
364 have resulted in a slight underestimate of the benefit of viral load testing before the introduc-
365 tion of dolutegravir-based first-line antiretroviral treatment regimens- but do reflect the likely
366 benefit moving forward. Fourth, while we have presented here the net present benefits of the
367 molecular diagnostics programme, the time horizon of the economic benefit associated with
368 health gains differ between diseases. Finally, we did not consider the impact of potential addi-
369 tional costs incurred as a result of test sensitivity given the uncertainty around the costs that
370 may occur as a consequence (e.g. false negative tests). Individuals who receive a false nega-
371 tive result may need to seek care again (or multiple times) to receive a correct diagnosis, in-
372 curring additional costs (most likely with TB testing, less so for SARS-CoV-2 given the short
373 duration of infection). These individuals may also transmit infection if they are diagnosed
374 negative (for TB, SARS-CoV-2, possibly for viral load if individuals think they are sup-
375 pressed; not likely for EID). It is unlikely, however, that these tests will influence our results
376 significantly, and the relative test sensitivity of molecular diagnostics is relatively high com-
377 pared to other available diagnostics.

378 **CONCLUSIONS**

379 In conclusion, the molecular diagnostics programme in South Africa is highly impactful, and
380 will continue to be an excellent investment of South African health expenditure. The value
381 and return on investment of these diagnostic tools is in line with other highly impactful public
382 health interventions and should continue to be valued as such. Into the future, molecular di-
383 agnostics are likely to play a more significant role in the monitoring and control of existing
384 diseases (other than those described here) and, as seen for SARS-CoV-2, may be the first
385 point of call for the diagnosis of and surveillance of future pandemics given their relative
386 ease of development and implementation into existing systems.

387
388
389

390 **Author Contributions:** Conceptualization, BEN, LES, WSS; methodology, BEN; formal
391 analysis, BEN, KHG, AXH, ANP, LJ; data curation, AdN, NC, LH, MPdS, KC, LES, WSS.;
392 writing—original draft preparation, BEN AdN; writing—review and editing, (NC, LH, MPdS,

393 KC, KHG, AXH, ANP, LJ, LES, WSS); All authors have read and agreed to the published
394 version of the manuscript.

395 **Funding:** Funding was received from the Bill and Melinda Gates Foundation, the South Af-
396 rican Medical Research Council and the National Institutes of Health. The funder had no role
397 in study design, data collection and analysis, decision to publish, or preparation of the manu-
398 script.

399

400 **Institutional Review Board Statement:** Not applicable

401 **Informed Consent Statement:** Not applicable

402

403 **Data Availability Statement:** The data are available *open access* in each relevant publication.
404 Any missing data points were imputed rather than from raw data.

405 **Conflicts of Interest:** The authors have no conflict of interest to declare.

406 REFERENCES

407

- 408 1. African Region - World Health Organization (W.H.O). REGIONAL STRATEGY ON
409 DIAGNOSTIC AND LABORATORY SERVICES AND SYSTEMS, 2023–2032 FOR THE
410 WHO AFRICAN REGION. Gaborone; 2023 Jul.
- 411 2. Fleming KA, Horton S, Wilson ML, Atun R, DeStigter K, Flanigan J, et al. The Lancet
412 Commission on diagnostics: transforming access to diagnostics. The Lancet [Internet].
413 2021 Nov 27 [cited 2024 Feb 7];398(10315):1997–2050. Available from:
414 <http://www.thelancet.com/article/S0140673621006735/fulltext>
- 415 3. Pai M, Walia K, Boehme CC. Essential medicines and essential diagnostics: a package
416 deal. Lancet Public Health [Internet]. 2019 Oct 1 [cited 2024 Feb 7];4(10):e492. Available
417 from: <http://www.thelancet.com/article/S2468266719301653/fulltext>
- 418 4. Boehme C, Hannay E, Pai M. Promoting diagnostics as a global good. Nature Medicine
419 2021 27:3 [Internet]. 2021 Mar 15 [cited 2024 Feb 7];27(3):367–8. Available from:
420 <https://www.nature.com/articles/s41591-020-01215-3>
- 421 5. Girdwood SJ, Crompton T, Cassim N, Olsen F, Sejake P, Diallo K, et al. Optimising
422 courier specimen collection time improves patient access to HIV viral load testing in
423 South Africa. Afr J Lab Med [Internet]. 2022 [cited 2024 Feb 9];11(1). Available from:
424 <https://pubmed.ncbi.nlm.nih.gov/36337769/>
- 425 6. Girdwood SJ, Crompton T, Sharma M, Dorward J, Garrett N, Drain PK, et al.
426 Cost-effectiveness of adoption strategies for point of care HIV viral load monitoring in
427 South Africa. EClinicalMedicine [Internet]. 2020 Nov 1 [cited 2024 Feb 9];28. Available
428 from: <https://pubmed.ncbi.nlm.nih.gov/33294817/>
- 429 7. National Health Laboratory Service. Annual Report 2022-2023 [Internet]. Johannesburg;
430 2023 [cited 2024 Mar 18]. Available from:
431 https://www.nhls.ac.za/wp-content/uploads/2023/11/241023-NHLS-Annual_Report.pdf
- 432 8. National health laboratory Service (NHLS). NHLS Annual Report 2021-2022 [Internet].
433 2022 [cited 2024 Mar 4]. Available from:
434 https://www.nhls.ac.za/wp-content/uploads/2022/10/NHLS_AR_2022_web_version.pdf

- 435 9. Messacar K, Parker SK, Todd JK, Dominguez SR. Implementation of rapid molecular
436 infectious disease diagnostics: The role of diagnostic and antimicrobial stewardship. *J*
437 *Clin Microbiol* [Internet]. 2017 Mar 1 [cited 2024 Feb 7];55(3):715–23. Available from:
438 <https://journals.asm.org/doi/10.1128/jcm.02264-16>
- 439 10. da Silva MP, Cassim N, Ndlovu S, Marokane PS, Radebe M, Shapiro A, et al. More Than
440 a Decade of GeneXpert®Mycobacterium tuberculosis/Rifampicin (Ultra) Testing in
441 South Africa: Laboratory Insights from Twenty-Three Million Tests. *Diagnostics* (Basel)
442 [Internet]. 2023 Oct 1 [cited 2024 Feb 9];13(20). Available from:
443 <https://pubmed.ncbi.nlm.nih.gov/37892074/>
- 444 11. Meyer-Rath G, Schnippel K, Long L, Macleod W, Sanne I. The Impact and Cost of Scal-
445 ing up GeneXpert MTB/RIF in South Africa. *PLoS One* [Internet]. 2012 [cited 2024 Feb
446 7];7(5):36966. Available from: www.plosone.org
- 447 12. Cepheid. Xpert® MTB/RIF. Sunnyvale, California;
- 448 13. Cepheid. Xpert® MTB/RIF Ultra [Internet]. Sunnyvale, California; [cited 2023 Sep 27].
449 Available from:
450 <https://www.cephheid.com/en-GB/tests/tb-emerging-infectious-diseases/xpert-mtb-rif-ultra.html>
451
- 452 14. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3:
453 diagnosis-rapid diagnostics for tuberculosis detection,2021 update. World Health Or-
454 ganization [Internet]. 2021 [cited 2024 Feb 7];Module 3:1–164. Available from:
455 <https://www.who.int/publications/i/item/9789240029415>
- 456 15. Azman AS, Golub JE, Dowdy DW. How much is tuberculosis screening worth? Esti-
457 mating the value of active case finding for tuberculosis in South Africa, China, and India.
458 *BMC Med* [Internet]. 2014 Oct 30 [cited 2024 Feb 7];12(1). Available from:
459 <https://pubmed.ncbi.nlm.nih.gov/25358459/>
- 460 16. Phillips A, Shroufi A, Vojnov L, Cohn J, Roberts T, Ellman T, et al. Sustainable HIV
461 treatment in Africa through viral-load-informed differentiated care. *Nature* [Internet].
462 2015 Dec 2 [cited 2024 Feb 9];528(7580):S68–76. Available from:
463 <https://pubmed.ncbi.nlm.nih.gov/26633768/>
- 464 17. Nichols B, Phillips A. Viral Loads and DALYs averted. Email communication. 2023.
- 465 18. Terris-Prestholt F, Boeras D, Ong JJ, Torres-Rueda S, Cassim N, Mbengue MAS, et al.
466 The potential for quality assurance systems to save costs and lives: the case of early in-
467 fant diagnosis of HIV. *Trop Med Int Health* [Internet]. 2020 Oct 1 [cited 2024 Feb
468 9];25(10):1235–45. Available from: <https://pubmed.ncbi.nlm.nih.gov/32737914/>
- 469 19. Haeri Mazanderani AF, Murray TY, Johnson LF, Ntloana M, Silere-Maqetseba T, Guo S,
470 et al. Eliminating Vertical Transmission of HIV in South Africa: Establishing a Baseline
471 for the Global Alliance to End AIDS in Children. *Diagnostics* 2023, Vol 13, Page 2563
472 [Internet]. 2023 Aug 1 [cited 2024 Feb 9];13(15):2563. Available from:
473 <https://www.mdpi.com/2075-4418/13/15/2563/htm>
- 474 20. Sherman GG, Cooper PA, Coovadia AH, Puren AJ, Jones SA, Mokhachane M, et al.
475 Polymerase chain reaction for diagnosis of human immunodeficiency virus infection in
476 infancy in low resource settings. *Pediatric Infectious Disease Journal* [Internet]. 2005

- 477 [cited 2024 Mar 22];24(11):993–7. Available from:
478 https://journals.lww.com/pidj/fulltext/2005/11000/polymerase_chain_reaction_for_diagnosis_of_human.14.aspx
479
- 480 21. Han AX, Girdwood SJ, Khan S, Sacks JA, Toporowski A, Huq N, et al. Strategies for
481 Using Antigen Rapid Diagnostic Tests to Reduce Transmission of Severe Acute Respiratory
482 Syndrome Coronavirus 2 in Low- and Middle-Income Countries: A Mathematical
483 Modelling Study Applied to Zambia. *Clin Infect Dis* [Internet]. 2023 Feb 15 [cited 2024
484 Feb 9];76(4):620–30. Available from: <https://pubmed.ncbi.nlm.nih.gov/36208211/>
- 485 22. FIND. TIDES-C19: The Infectious Disease and Epidemic Simulation for COVID-19 [Internet].
486 *Economist Impact*. 2022 [cited 2024 Feb 9]. Available from:
487 <https://impact.economist.com/health/tides/covid-19/>
- 488 23. Lee J, Song JU. Diagnostic accuracy of the Cepheid Xpert Xpress and the Abbott ID NOW assay
489 for rapid detection of SARS-CoV-2: A systematic review and meta-analysis. *J Med Virol* [Internet].
490 2021 Jul 1 [cited 2024 Mar 22];93(7):4523–31. Available from:
491 <https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.26994>
- 492 24. Hans L, Cassim N, Sarang S, Hardie D, Ndlovu S, Venter WDF, et al. HIV Viral Load Testing in
493 the South African Public Health Setting in the Context of Evolving ART Guidelines and Advances
494 in Technology, 2013–2022. *Diagnostics* 2023, Vol 13, Page 2731 [Internet]. 2023 Aug 22
495 [cited 2024 Feb 9];13(17):2731. Available from:
496 <https://www.mdpi.com/2075-4418/13/17/2731/htm>
- 497 25. Scott LE, Hsiao NY, Dor G, Hans L, Marokane P, da Silva MP, et al. How South Africa Used
498 National Cycle Threshold (Ct) Values to Continuously Monitor SARS-CoV-2 Laboratory Test
499 Quality. *Diagnostics* 2023, Vol 13, Page 2554 [Internet]. 2023 Aug 1 [cited 2024 Feb
500 9];13(15):2554. Available from: <https://www.mdpi.com/2075-4418/13/15/2554/htm>
- 501 26. Radebe L, Haeri Mazanderani A, Sherman GG. Indeterminate HIV PCR results within South
502 Africa’s early infant diagnosis programme, 2010–2019. *Clinical Microbiology and Infection*.
503 2022 Apr 1;28(4):609.e7-609.e13.
- 504 27. UNICEF. UNICEF Data - Country Profiles. 2022 [cited 2024 Feb 9]. South Africa (ZAF) - Demographics,
505 Health & Infant Mortality. Available from: <https://data.unicef.org/country/zaf/>
- 506 28. Exchange Rates UK. US Dollar to South African Rand Spot Exchange Rates for 2022 [Internet].
507 2022 [cited 2024 Mar 4]. Available from:
508 <https://www.exchangerates.org.uk/USD-ZAR-spot-exchange-rates-history-2022.html>
- 509 29. Coetsee L, Hirasen K, Jamieson L, Evans D, Meyer-Rath G. Linganisa TB Cost Model, South
510 Africa. Johannesburg: Health Economics and Epidemiology Research Office, University of the
511 Witwatersrand; 2022.
- 512 30. Meyer-Rath G, van Rensburg C, Chiu C, Leuner R, Jamieson L, Cohen S. The per-patient costs
513 of HIV services in South Africa: Systematic review and application in the South African HIV
514 Investment Case. *PLoS One* [Internet]. 2019 Feb 1 [cited 2024 Feb 23];14(2):e0210497. Available
515 from: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0210497>
- 516 31. Phillips A, Shroufi A, Vojnov L, Cohn J, Roberts T, Ellman T, et al. Sustainable HIV Treatment
517 in Africa through Viral Load-Informed Differentiated Care. *Nature* [Internet]. 2015 Dec 12
518 [cited 2024 Mar 4];528(7580):S68. Available from: [/pmc/articles/PMC4932825/](https://pmc/articles/PMC4932825/)

- 519 32. Ozawa S, Clark S, Portnoy A, Grewal S, Brenzel L, Walker DG. Return On Investment From
520 Childhood Immunization In Low- And Middle-Income Countries, 2011-20. *Health Aff (Mill-*
521 *wood)* [Internet]. 2016 [cited 2024 Feb 9];35(2):199–207. Available from:
522 <https://pubmed.ncbi.nlm.nih.gov/26858370/>
- 523 33. Johns Hopkins University - International Vaccine Access Center (IVAC). Methodology Report:
524 Decade of Vaccines Economics (DOVE) Return on Investment Analysis. [Internet]. 2019 [cited
525 2024 Feb 9]. Available from: <http://immunizationeconomics.org/dove-roi>
- 526 34. Sah P, Vilches TN, Moghadas SM, Pandey A, Gondi S, Schneider EC, et al. Return on Invest-
527 ment of the COVID-19 Vaccination Campaign in New York City. *JAMA Netw Open* [Internet].
528 2022 Nov 1 [cited 2024 Feb 9];5(11):e2243127. Available from:
529 <https://pubmed.ncbi.nlm.nih.gov/36409495/>
- 530 35. Lamontagne E, Over M, Stover J. The economic returns of ending the AIDS epidemic as a pub-
531 lic health threat. *Health Policy (New York)*. 2019 Jan 1;123(1):104–8.
- 532 36. UNAIDS. Fast-Track: Ending the AIDS epidemic by 2030 [Internet]. Geneva; 2014 [cited 2024
533 Feb 9]. Available from:
534 https://www.unaids.org/sites/default/files/media_asset/JC2686_WAD2014report_en.pdf
- 535 37. National Institute of Communicable Diseases. National Surveillance Dashboards. 2022 [cited
536 2024 Mar 5]. Microbiologically Confirmed Pulmonary TB - South Africa. Available from:
537 [https://mstrweb.nicd.ac.za/MicroStrategy/asp/Main.aspx?Server=NICDSANDMSTRI01&Proje-](https://mstrweb.nicd.ac.za/MicroStrategy/asp/Main.aspx?Server=NICDSANDMSTRI01&Project=Surveillance&Port=0&evt=2048001&src=Main.aspx.2048001&documentID=4236FF364F683E2F257DA5AC647F5BA6¤tViewMedia=1&visMode=0)
538 [ct=Surveillance&Port=0&evt=2048001&src=Main.aspx.2048001&documentID=4236FF364F683E](https://mstrweb.nicd.ac.za/MicroStrategy/asp/Main.aspx?Server=NICDSANDMSTRI01&Project=Surveillance&Port=0&evt=2048001&src=Main.aspx.2048001&documentID=4236FF364F683E2F257DA5AC647F5BA6¤tViewMedia=1&visMode=0)
539 [2F257DA5AC647F5BA6¤tViewMedia=1&visMode=0](https://mstrweb.nicd.ac.za/MicroStrategy/asp/Main.aspx?Server=NICDSANDMSTRI01&Project=Surveillance&Port=0&evt=2048001&src=Main.aspx.2048001&documentID=4236FF364F683E2F257DA5AC647F5BA6¤tViewMedia=1&visMode=0)
- 540 38. Stop TB Partnership. World TB Day Theme. 2022 [cited 2024 Feb 9]. Invest to End TB. Save
541 Lives. Available from: <https://www.stoptb.org/news/invest-to-end-tb-save-lives>
- 542 39. Mzembe T, Lessells R, Karat AS, Randera-Rees S, Edwards A, Khan P, et al. Prevalence
543 and Risk Factors for Mycobacterium tuberculosis Infection Among Adolescents in Rural
544 South Africa. *Open Forum Infect Dis* [Internet]. 2021 Jan 1 [cited 2024 Feb 9];8(1).
545 Available from: [/pmc/articles/PMC7814392/](https://pubmed.ncbi.nlm.nih.gov/36409495/)

546

547